NCT07177872View on ClinicalTrials.gov

A Long-term Efficacy and Safety of NTQ5082 Capsules

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

June 30, 2026

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
DRUG

NTQ5082 capsules 200 mg

NTQ5082 capsules 200 mg

Trial Locations (1)

300020

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences ,, Tianjin

Sponsors
All Listed Sponsors
lead

Nanjing Chia-tai Tianqing Pharmaceutical

INDUSTRY